DBV Technologies S.A. (DBVT)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$11.56−$0.0400 (−0.34%) on the dayAs of the close; data may be delayed.
DBVT price, last 12 months
Key stats
- Previous close
- $11.60
- Open
- $11.41
- Day range
- $11.40 – $11.83
- 52-week range
- $8.86 – $26.19
- Volume
- 290K
- Avg volume (20 days)
- 318K
- Market cap
- $726.5M
Performance
1W−6.4%
1M−20.4%
3M−27.8%
6M−42.8%
YTD−39.7%
1Y+23.5%
vs S&P 500, 1Y+6.7 pts
Technicals and fundamentals
About DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $726.5M